Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1657
    -0.0026 (-0.22%)
     

  • GBP/USD

    1.2549
    +0.0016 (+0.13%)
     

  • Bitcoin GBP

    50,255.49
    +3,310.63 (+7.05%)
     

  • CMC Crypto 200

    1,358.42
    +81.44 (+6.38%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    78.01
    -0.94 (-1.19%)
     

  • GOLD FUTURES

    2,309.80
    +0.20 (+0.01%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

BUZZ-AstraZeneca: Pfizer may turn M&A sights on Mylan -Jefferies

Reuters - UK Focus

** Pfizer (NYSE: PFE - news) can resume its pursuit of AstraZeneca (NYSE: AZN - news) from today as 6-month cooling-off period ends but chances of a fresh bid seen as slim, especially after the U.S. drugmaker's big oncology deal with Merck KGaA (Other OTC: MKGAF - news) last week.

** Jefferies analysts reckon Mylan (NasdaqGS: MYL - news) , which is buying some of Abbott's established drugs, now the most likely target for Pfizer, with GlaxoSmithKline "a wild card", since buying top UK drugmaker would provoke political storm.

** Actavis (NYSE: ACT - news) , once seen as main "Plan B" target for Pfizer, may now also be off the table following its proposed acquisition of Allergan (NYSE: AGN - news) .

** AstraZeneca shares are flat in early trade. (RM (LSE: RM.L - news) : ben.hirschler.thomsonreuters.com@reuters.net)